Hi
@otherperspectivere "
That’s the Eric Rose that wants to buy an additional 1.5m shares you may recall.", I think the 1.5m is the rough price.
I think we'll find (come the 30 November AGM) that Dr Rose wants to pay for an additional
5,039,814 shares (@AUD0.30 allotment price). Link
here. Oh yes, Dr Rose knows very well what he's doing, and (by necessary implication) what Mesoblast's doing.
And I think he wants all us Mesoblast holders to know that as well. That's my kind of insider trading (but I do have mixed feelings about that price he's looking for - I guess I might feel better about it with 2 FDA indication approvals under our belt, or if he were to waive an equivalent number of his extant but unexercised MSB options).
And re your very apt (rhetorical) question to the prick " ...
how useful is a new clinical trial based against a surrogate endpoint designed to show durability of effect when the FDA already have spectacular four year actual mortality data for Ryoncil from GVHD001 . In contrast the only approved therapy for over 12 years old,Ruxolitinib, has shown in Reach 2, that it doesn’t not have durability of effect in severe grade disease relative to controls based on longer than 12 month endpoints.", have you seen what Novartis has done in going about hiding its pediatric morbidity & mortality data from
REACH-4?Despite the topline ORR figures being gushingly published all over the place e.g. at ASH 2022 (see this useful article:
https://docwirenews.com/post/ruxolitinib-with-corticosteroids-in-pediatric-gvhd), there is
still no mortality or morbidity data published by Novartis. Instead, Novartis has carried out unspecified research at its own Novartis Investigation Sites at different places around the world. Run by Novartis clinicians. With all records provided & maintained by Novartis personnel. It's a scary trial to dig into, IMO.
And let me know when you find the mortality/ morbidity data. It's just missing. Why?
I don't think attending physicians will be fooled for a minute, & I think they'll want the curative value of RYONCIL for their patients - paediatric or adult - but there's no doubt in my mind we're in the middle of a war (of values, of ethics & its a big $$ deal). I believe Novartis is preparing for Mesoblast's entry into what has been, effectively, their exclusive market as follows:
- first, by publishing as broadly as they can that Novartis/ Incyte now have their own
paediatric data which justify off-label use of Ruxolitinib (& even dosing) in kids [ But they won't apply for approval first!! They won't put that data up to the FDA for prior approval, as Mesoblast has done. Oh no. ] , &
- second, by saying to the world: Well we all know & accept that Ruxolitinib is the inhibitor immuno-suppressant that deals with the front line aGVHD problems after or alongisde corticosteroids, but these new treatments for aGVHD like...oh...I don't know....say BM-MSCs, they work ON DIFFERENT THINGS and can be used as a regenerative treatment
IN ADDITION. Yes, that will work fine. Ruxolitinib will continue to be prescribed, of course, & these newer treatments can be added if you like for some extra
REGENERATIVE effect (if you really want, but its up to you).
Think I'm misreading it a little? I'd be interested in your thoughts on this one: link
here
Yeah. They know we're coming alright.
To me this is how Novartis & Incyte are going to try to keep their multi-billion dollar market revenues intact, when we enter their pool.
The sooner we get in there, the better. For the kids.
Cheers
(20min delay)